Parallel Artificial Membrane Permeability Assay (PAMPA) is a cell-free permeation model used to predict passive drug transport. Passive diffusion is an important factor in determining the absorption of orally administered compounds in the gastrointestinal tract (GIT), penetration of the blood-brain barrier (BBB), and general transport across cell membranes. PAMPA provides a simplified method by addressing only a single transport mechanism, avoiding the complexities of active transport and metabolism.
Depending on the lipid and buffers used, PAMPA can predict gastrointestinal tract absorption (PAMPA-GIT), blood-brain barrier permeability (PAMPA-BBB) or transdermal penetration (Skin-PAMPA). Generally, PAMPA is carried out in the early phase of drug discovery to select leads with promising oral bioavailability/brain penetration potential by ranking candidates in a cost-effective manner. By combining the data generated in PAMPA with more labor-intensive (as well as more predictive) cell-based permeability assays, quick structural modification of discovery compounds can be efficiently guided.
The PAMPA assay for permeability measurement is based on the diffusion of a compound of interest through an artificial membrane. The PAMPA artificial membrane has a lipid-oil-lipid tri-layer structure constructed in the pores of a porous filter. The oil layer in the middle, which maintains a robust and stable PAMPA membrane, is ultra-thin to minimize compound retention and interference with the compound permeation.
Using Creative Bioarray's ADME screening services is the fastest and most cost-effective way to get permeability predictions for your compounds. For more detailed information, please feel free to contact us or sent us an inquiry directly.